Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02438995
Other study ID # 15-182
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date May 2015
Est. completion date June 2021

Study information

Verified date October 2021
Source Northwell Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date June 2021
Est. primary completion date June 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female patients of =18 years of age. 2. Patients with a documented diagnosis of recurrent head and neck squamous cell cancer (squamous cell carcinoma, including nasopharyngeal cancer, or adenoid cystic carcinoma). Patients must have at least one confirmed and evaluable tumor site.* The recurrence must have bidimensional measurements by clinical examination or CT/MRI/PET scan. A confirmed recurrence site may also be biopsy-proven 3. Tumor Recurrence which is surgically unresectable 4. Patients must have a Karnofsky performance status =70% (or the equivalent ECOG level of 0-2) (see Appendix Performance Status Evaluation) and an expected survival of = three months. 5. Patients must have adequate hematologic reserve with WBC=3000/mm3, absolute neutrophils =1500/mm3 and platelets =100,000/ mm3. Patients who are on Coumadin must have a platelet count of =150,000/ mm3 6. Pre-enrollment chemistry parameters must show: bilirubin<1.5X the institutional upper limit of normal (IUNL); AST or ALT<2.5X IUNL and creatinine<1.5X IUNL. 7. Pre-enrollment coagulation parameters (PT and PTT) must be =1.5X the IUNL. 8. Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study. 9. Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening. 10. Patients who refuse surgery. Exclusion Criteria: 1. Women who are pregnant or lactating. 2. Women of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period. 3. Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring. 4. Pre-existing cardiac or respiratory disorders 5. Unrelated malignancy within 3 years 6. History of hypersensitivity reactions to other EGFR inhibitors 7. Metastatic disease 8. Less than 6 months from prior Radiation Therapy (Arm 1) 9. Previous exposure to Cetuximab

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intraarterial Cetxuimab (Erbitux)
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)

Locations

Country Name City State
United States Lenox Hill Hospital New York New York

Sponsors (1)

Lead Sponsor Collaborator
Northwell Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The maximum tolerated dose (MTD) of superselective intraarterial Cetuximab. 30 days
Primary Descriptive frequency of subjects experiencing toxicities. 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT02743832 - A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma. N/A
Active, not recruiting NCT02229656 - Olaparib and Radiotherapy in Head and Neck Cancer Phase 1
Completed NCT00389727 - Simultaneous Integrated Boost (SIB)- IMRT Phase 2
Recruiting NCT02328391 - STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE N/A
Completed NCT00875381 - Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin N/A
Completed NCT00534950 - Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck N/A
Terminated NCT00073450 - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) Phase 2
Terminated NCT01441128 - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05970497 - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01362127 - Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia Phase 2
Completed NCT00240682 - Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Phase 2
Terminated NCT02254044 - Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus Phase 1
Active, not recruiting NCT00829192 - Phase II AK Study in Organ Transplant Patients Phase 2
Completed NCT00313027 - Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation N/A
Completed NCT00539630 - TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN Phase 3
Recruiting NCT04564989 - Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Not yet recruiting NCT06094829 - Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
Recruiting NCT04481256 - TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY N/A
Active, not recruiting NCT02664935 - National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer Phase 2
Terminated NCT00673049 - Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer Phase 3